What does this research mean for the field?

A seasonal RSVpreF vaccination strategy is the only cost-effective approach for preventing RSV-associated disease among Japanese infants under a willingness-to-pay threshold of JPY 5,000,000 (US$33,333) per QALY. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

synapse

⌘+K

synapse

⌘+K

March 3, 2026Open Access

Economic Impact of Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination and Nirsevimab Prophylaxis on Respiratory-Syncytial-Virus-Associated Disease Among Japanese Infants

Key Points

The seasonal RSV preF vaccination strategy is identified as cost-effective, indicating a favorable economic outcome for healthcare systems.
Analysis suggests a threshold of JPY 5,000,000 or US$33,333 per quality-adjusted life year (QALY) as the benchmark for cost-effectiveness evaluation.

Structured PICO

Is Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination or Nirsevimab Prophylaxis cost-effective for preventing RSV-associated disease in Japanese infants?

Population

Japanese infants

Intervention

Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination (RSVpreF) and Nirsevimab Prophylaxis

Outcome

Cost-effectiveness (Quality-Adjusted Life Years / QALY)

Seasonal RSVpreF vaccination is a cost-effective strategy for preventing RSV-associated disease in Japanese infants at a threshold of US$33,333 per QALY.

Abstract

Only seasonal RSVpreF strategy is cost-effective under the JPY5 000 000/US33 333 per QALY willingness-to-pay threshold.

Economic Impact of Respiratory Syncytial Virus Prefusion F Protein-Based Vaccination and Nirsevimab Prophylaxis on Respiratory-Syncytial-Virus-Associated Disease Among Japanese Infants

Key Points

Structured PICO

Abstract

Cite This Study